Articles tagged with: Valproic Acid
Headline, News »
The addition of valproic acid (Depakene) to Dacogen (decitabine) may not improve response rates compared to Dacogen alone in the treatment of myelodysplastic syndromes (MDS) due to valproic acid blocking how Dacogen works.
The findings are from a Phase 2 study conducted by researchers at the M.D. Anderson Cancer Center in Houston and were presented at the 51st annual American Society of Hematology (ASH) meeting and exposition held in New Orleans in December.
Valproic acid activates the production of protein based on a person’s genes by inhibiting an enzyme called…
Headline, News »
A combination therapy of Vidaza (azacitidine) and valproic acid (Depakene) may be more effective than Vidaza alone for the treatment of myelodysplastic syndromes (MDS), according to a Phase 2 study published in the journal Clinical Cancer Research.
Valproic acid is commonly used to reduce seizures in epilepsy patients and to treat bipolar disorder. It has recently become of interest as a possible treatment for blood- and bone marrow-related cancers like MDS.
Previous studies have shown that two classes of drugs, hypomethylating agents, which include Vidaza, and histone deacetylase inhibitors, which…